Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
The association between allostatic load and lymphedema in breast cancer survivors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Obeng-Gyasi Barnabas, Gokun Yevgeniya, Elsaid Mohamed I, Chen J C, Andersen Barbara L, Carson William E, Jhawar Sachin, Anampa Jesus D, Quiroga Dionisia, Skoracki Roman, Obeng-Gyasi Samilia
Аннотация
PURPOSE: Allostatic load, a measure of physiological dysregulation secondary to chronic exposure to socioenvironmental stressors, is associated with 30-day postoperative complications and mortality in patients with breast cancer. This study aimed to examine the association between allostatic load (AL) at diagnosis and development of breast cancer-related lymphedema (BCRL).
METHODS: Patients aged 18 years or older who received surgical treatment for stage I-III breast cancer between 2012 and 2020 were identified from The Ohio State University Cancer Registry. AL was calculated using biomarkers from the cardiovascular, metabolic, renal, and immunologic systems. A high AL was defined as AL > median. Logistic regression analyses examined the association between AL and BRCL, adjusting for sociodemographic, clinical, and treatment factors.
RESULTS: Among 3,609 patients, 18.86% (n = 681) developed lymphedema. A higher proportion of patients with lymphedema were Black (11.89% vs. 7.38%, p < 0.0001), Medicaid insured (12.19% vs. 6.97%, p < 0.0001), had stage 3 disease (7.05% vs. 1.57%, p < 0.0001), and had a high AL (53.63% vs. 46.90%, p = 0.0018). In adjusted analysis, high AL was associated with higher odds of developing lymphedema than low AL (OR 1.281 95% CI 1.06-1.55). Moreover, a 1-unit increase in AL was associated with 10% higher odds of lymphedema (OR 1.10, 95% CI 1.04-1.16). There was no statistically significant association between AL and severity of lymphedema (OR 1.02, 95% CI 0.82-1.23).
CONCLUSION: In this retrospective cohort of breast cancer survivors, high AL at diagnosis was associated with higher odds of developing lymphedema. Future research should elucidate the pathways by which AL influences lymphedema.
METHODS: Patients aged 18 years or older who received surgical treatment for stage I-III breast cancer between 2012 and 2020 were identified from The Ohio State University Cancer Registry. AL was calculated using biomarkers from the cardiovascular, metabolic, renal, and immunologic systems. A high AL was defined as AL > median. Logistic regression analyses examined the association between AL and BRCL, adjusting for sociodemographic, clinical, and treatment factors.
RESULTS: Among 3,609 patients, 18.86% (n = 681) developed lymphedema. A higher proportion of patients with lymphedema were Black (11.89% vs. 7.38%, p < 0.0001), Medicaid insured (12.19% vs. 6.97%, p < 0.0001), had stage 3 disease (7.05% vs. 1.57%, p < 0.0001), and had a high AL (53.63% vs. 46.90%, p = 0.0018). In adjusted analysis, high AL was associated with higher odds of developing lymphedema than low AL (OR 1.281 95% CI 1.06-1.55). Moreover, a 1-unit increase in AL was associated with 10% higher odds of lymphedema (OR 1.10, 95% CI 1.04-1.16). There was no statistically significant association between AL and severity of lymphedema (OR 1.02, 95% CI 0.82-1.23).
CONCLUSION: In this retrospective cohort of breast cancer survivors, high AL at diagnosis was associated with higher odds of developing lymphedema. Future research should elucidate the pathways by which AL influences lymphedema.